Tumors harboring gene fusions previously described in naïve NSCLC tumors, even concerning unusual partners and breakpoints, seem to respond or control disease under treatments targeting the gene, such as for ALK, RET fusions, usually with maintaining EGFR-TKI [132]. The gene discussed is RET; the disease is non-small cell lung carcinoma.